Modulation of dopaminergic transmission by alpha-noradrenergic agonists and antagonists: evidence for antidopaminergic properties of some alpha antagonists.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003000:Clonidine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006220:Haloperidol / Q000494:pharmacology; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D013134:Spiperone / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects; D015016:Yohimbine / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D015102:3,4-Dihydroxyphenylacetic Acid; D015016:Yohimbine; D013134:Spiperone; D006220:Haloperidol; D003000:Clonidine; D004298:Dopamine; D006719:Homovanillic Acid; D011224:Prazosin